Product Images Argatroban

This appears to be a table showing the concentration (in mcg/mL) of the drug Argatroban at various doses (in mcg/kg/min) during plasma infusion. There are also some symbols and characters that are not clearly readable.*

This is a description of a study involving a Historical Control group with N=147. The study followed up for a period of 37 days and there were no clinical endpoints observed in the censored group (defined as death, amputation or new thrombosis). The graph shows the study days (0, 7, 14, 21, 28, 35) and a p-value of 0.007 is provided.*

The text appears to be a statistical report of a study comparing the effectiveness of Argatroban versus historical control in preventing clinical endpoint events such as death or thrombosis. The study had 144 participants with 81 censored data points and a p-value of 0.018. The historical control group had 46 participants with 20 censored data points. The graph shows the progression of the study over a follow-up period of up to 37 days.*

Argatroban is an injection that comes in a 25 mL single-dose vial for intravenous infusion only. It contains Argatioten, D-sortol, and denyaed loonol. Dilution and usual adult dosage instructions can be found in the accompanying prescribing information. The drug must be stored at room temperature and not frozen. This product is distributed by Amneal Pharmaceuticals LLC. Lot and expiration information are also included. Dilution prior to use is necessary.*

This is a product description for Argatroban Injection by Amneal Pharmaceuticals. It is a solution for intravenous infusion only, containing 250mg/2.5mL of Argatroban, 1750mg of D-Sotal, and 1000mg of Senyoraied Aconal. The solution does not contain preservatives and should be stored at a temperature of 20°C to 25°C. Dilution is necessary before the solution is used. The product is packaged in a 25 mL single-dose vial and should be protected from light prior to dilution. For more information, please refer to the prescribing information.*